drugset / Trial / NCT05885269

Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata

NCT05885269

Phase 1 Completed 70 enrolled Combined Military Hospital Abbottabad
RandomizedParallel-groupOpen-labelTreatment

Summary

Methodology: The 70 patients of age 20 to 50 years presented to the out-patient department of CMH Abbottabad suffering from alopecia areata were enrolled. The non-probability consecutive sampling technique was used. Patient in group-A applied clobetasol propionate 0.05% twice daily, whereas Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months. The Patients were assessed at baseline, 4th weeks, 8th week and 12th week after treatment of each session. Hair loss was calculated from SALT score at presentation and on follow-up after 3 months. The degree of response was assessed on the basis of hair re-growth as excellent (\>75% re-growth), Marked (51-75% re-growth), moderate (26-50% re-growth), or slight (≤25% re-growth). To determine statistical significance χ2-square test, taking p-value \<0.05 as significant, was used.

Timeline

Start
2022-11-01
Primary completion
2023-04-30
Completion
2023-04-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tacrolimus Small molecule 0.1 % Topical
Comparator clobetasol propionate Small molecule 0.05 % Topical

Indications